

Albius Sciences Group started as the “spin-off” of ***In Silico* drug design research programme from the Oita University, Japan.**

This research programme involved the use of **advanced chemical techniques coupled with AI technology** and the creation of a **compound library.**



FOUR SEGMENTS OF ALBIUS SCIENCES BIOTECH PLATFORM



Albius In Silico

The novel small molecule drug design technology (including AI technology and 3D modelling).




Albius Compound Library

A compound library, created with advanced chemical technique, resulting in discovery of new chemical spaces.



Albius Human Health

Multiple pipelines of small molecule drug R&D for target diseases including fibrosis, respiratory syncytial virus (RSV) and coronavirus



Albius Animal Health

Multiple pipelines of small molecule drug R&D for target diseases, including feline infectious peritonitis (FIP), feline chronic renal failure, SADS-CoV, African swine fever and avian flu.


OUR TALENTS & LOCATIONS

Our Leadership Team is the integration of international and multidisciplinary experiences, including private equity, life sciences and technology start-ups.

Our Scientific Technology Team Under the leadership of our CTO, Prof. Shigeru Matsuoka, located in Japan and Hong Kong, accounting for:

- 9 PhDs
- 24 patent applications
- 437 published research papers

(*In 2024, the team will expand into Austria and Singapore.)



CONTACT US

Heinrich Grabner (CEO)
hgrabner@albiussci.com

Stephanie Luo (COO)
stephanie.luo@albiussci.com

Marvin Kan (CAO)
marvin.kan@albiussci.com